NASDAQ:VERA

Vera Therapeutics (VERA) Stock Price, News & Analysis

Vera Therapeutics logo
$25.45 -1.30 (-4.86%)
Closing price 04:00 PM Eastern
Extended Trading
$25.44 -0.01 (-0.04%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Vera Therapeutics Stock (NASDAQ:VERA)

Advanced

Key Stats

Today's Range
$25.16
▼
$27.15
50-Day Range
$25.58
▼
$36.26
52-Week Range
$25.08
▼
$56.05
Volume
1.37 million shs
Average Volume
1.61 million shs
Market Capitalization
$1.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.93
Consensus Rating
Moderate Buy

Company Overview

Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs.

Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases. The candidate is investigational and has not been approved for commercial use.

Vera was founded by physician and biotechnology executive Marshall Fordyce, who serves as the company’s chief executive officer. Its development work and clinical trials support its efforts to advance potential treatments for patients in the United States and other regions.

AI Generated. May Contain Errors.

Vera Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

VERA MarketRank™: 
3.444962942625 of 5 stars

Vera Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 210th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 11 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Vera Therapeutics has a consensus price target of $74.93, representing about 194.4% upside from its current price of $25.45.

  • Amount of Analyst Coverage

    Vera Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vera Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vera Therapeutics are expected to grow in the coming year, from ($6.00) to ($3.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vera Therapeutics is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vera Therapeutics is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vera Therapeutics has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    20.03% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 8.47.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently decreased by 10.64%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vera Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vera Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Vera Therapeutics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Vera Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    9 people have searched for VERA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,334,220.00 in company stock.

  • Percentage Held by Insiders

    15.90% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vera Therapeutics' insider trading history.
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VERA Stock News Headlines

Vera Therapeutics Earnings Call Highlights TRUTAKNA Momentum
J.P. Morgan Remains a Buy on Vera Therapeutics (VERA)
Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
HC Wainwright Lifts Earnings Estimates for Vera Therapeutics
Vera Therapeutics (VERA) Receives a Hold from Wedbush
Vera Therapeutics (VERA) Q3 2026 Earnings Call Transcript
See More Headlines

VERA Stock Analysis - Frequently Asked Questions

Vera Therapeutics' stock was trading at $50.64 on January 1st, 2026. Since then, VERA shares have decreased by 49.7% and is now trading at $25.45.

Vera Therapeutics, Inc. (NASDAQ:VERA) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($1.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.62) by $0.32. The business had revenue of $10.28 million for the quarter, compared to analysts' expectations of $3.42 million.
Read the conference call transcript
.

Vera Therapeutics (VERA) raised $65 million in an initial public offering on Thursday, May 13th 2021. The company issued 4,350,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO.

Vera Therapeutics' top institutional shareholders include State Street Corp (4.58%), Pictet Asset Management Holding SA (2.55%), Integral Health Asset Management LLC (2.08%) and Goldman Sachs Group Inc. (1.97%). Insiders that own company stock include Commodore Capital Lp, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Laurence Matthew Skelton, Robert Brenner, David Lee Johnson, William D Turner and Patrick G Enright.
View institutional ownership trends
.

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include Iovance Biotherapeutics (IOVA), Palantir Technologies (PLTR), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA) and Intel (INTC).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VERA
CIK
1831828
Fax
N/A
Employees
362
Year Founded
2016

Price Target and Rating

High Price Target
$125.00
Low Price Target
$29.00
Potential Upside/Downside
+194.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$299.61 million
Net Margins
N/A
Pretax Margin
-4,041.18%
Return on Equity
-90.03%
Return on Assets
-70.54%

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
7.91
Quick Ratio
7.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.61 per share
Price / Book
5.52

Miscellaneous

Outstanding Shares
72,300,000
Free Float
60,803,000
Market Cap
$1.84 billion
Optionable
Optionable
Beta
1.07

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:VERA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners